Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Transduction01:16

Transduction

Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic and transcriptional effects of bazedoxifene/conjugated estrogens in a model of obesity-associated breast cancer risk.

JCI insight·2025
Same author

Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.

Clinical breast cancer·2025
Same author

Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.

Contemporary clinical trials·2024
Same author

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.

Breast cancer research : BCR·2024
Same author

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

Menopause (New York, N.Y.)·2024
Same author

Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells.

PloS one·2022

Related Experiment Video

Updated: May 14, 2026

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
14:13

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory

Published on: January 1, 2018

Evolution of the tissue selective estrogen complex (TSEC).

Barry S Komm1, Sebastian Mirkin

  • 1Pfizer, Inc., Collegeville, Pennsylvania 19426, USA. barry.komm@pfizer.com

Journal of Cellular Physiology
|January 30, 2013
PubMed
Summary
This summary is machine-generated.

Tissue selective estrogen complexes (TSECs) offer menopausal therapy benefits by pairing selective estrogen receptor modulators (SERMs) with estrogens. TSECs provide estrogenic effects without stimulating breast and uterine tissues, unlike traditional estrogen therapy.

More Related Videos

Using Tg(Vtg1:mcherry) Zebrafish Embryos to Test the Estrogenic Effects of Endocrine Disrupting Compounds
12:02

Using Tg(Vtg1:mcherry) Zebrafish Embryos to Test the Estrogenic Effects of Endocrine Disrupting Compounds

Published on: August 8, 2020

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Experiment Videos

Last Updated: May 14, 2026

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
14:13

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory

Published on: January 1, 2018

Using Tg(Vtg1:mcherry) Zebrafish Embryos to Test the Estrogenic Effects of Endocrine Disrupting Compounds
12:02

Using Tg(Vtg1:mcherry) Zebrafish Embryos to Test the Estrogenic Effects of Endocrine Disrupting Compounds

Published on: August 8, 2020

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Area of Science:

  • Endocrinology and Pharmacology
  • Molecular Biology
  • Women's Health

Background:

  • Estrogens regulate cellular processes via estrogen receptors (ERs) in tissues like bone, breast, and endometrium.
  • Estrogen therapy benefits women with estrogen deficiency but can stimulate breast and uterine tissues.
  • Selective estrogen receptor modulators (SERMs) offer tissue-specific agonist or antagonist activity.

Purpose of the Study:

  • To explore the distinct molecular and pharmacologic effects of estrogens, SERMs, and tissue selective estrogen complexes (TSECs).
  • To evaluate the efficacy of TSECs in maintaining estrogenic benefits while mitigating adverse tissue stimulation.
  • To understand the mechanisms underlying TSEC action in various tissues.

Main Methods:

  • Preclinical studies involving cultured breast cancer cells and animal models.
  • Analysis of gene expression profiles associated with different TSECs and their components.
  • Biochemical analyses to investigate ER degradation as a TSEC mechanism.

Main Results:

  • TSECs demonstrated distinct gene expression profiles compared to individual SERMs and estrogens.
  • Studies showed a lack of estrogen-induced stimulation in mammary glands and endometrium with TSECs.
  • ER degradation was identified as a key mechanism for TSEC antagonistic effects in the breast.
  • TSECs exhibited positive effects in bone and the central nervous system, similar to estrogens.

Conclusions:

  • Estrogens, SERMs, and TSECs exert distinct, tissue-specific molecular and pharmacologic effects.
  • TSECs represent a novel approach to menopausal therapy, balancing estrogenic benefits with reduced tissue stimulation.
  • Further research is needed to clarify the mechanisms of TSEC activity in tissues like bone and the central nervous system.